NOB1 Antibody

1. A detailed characterization of Nob1 organization and its interaction with Pno1. PMID: 30176151
2. These results suggested that RIOK2 and NOB1 may be potential targets in the treatment of Non-small cell lung cancer (NSCLC), and miR145 may be considered a therapeutic inhibitor of both genes. PMID: 29749434
3. our results indicate that miR-330-5p inhibits non-small-cell lung cancer (NSCLC) cell growth through downregulation of NOB1 expression. Our study suggests that miR-330-5p may serve as a potential therapeutic target for the treatment of NSCLC PMID: 28849232
4. RIOK2 and NOB1 were highly expressed in NSCLC cells and tissues, and their expression profiles were significantly associated with the Tumour Node Metastasis (TNM) clinical stage, lymph node metastasis, and differentiation. RIOK2 expression was correlated with NOB1. PMID: 27346559
5. The proto-oncogene NOB1 as a direct target of miR-326 in gastric cancer. PMID: 27733214
6. The expression of NOB1 was also found to be higher in multidrug-resistant gastric cancer cells than that of sensitive cells. This novel MAb will be valuable for investigating the role of NOB1 in carcinogenesis and multidrug resistance of gastric cancer. PMID: 27097067
7. CONCLUSION: Our results suggest that enhanced expression of NOB1 related with poor early response to cisplatin-based chemotherapy in patients with advanced non-small cell lung cancer PMID: 25971309
8. NOB1 plays an oncogenic role in laryngeal cancer cells through the regulation of JNK signaling pathway. PMID: 27035645
9. miR-139-3p may act as a tumor suppressor that can inhibitcervical cancer cell proliferation, migration and invasion and induce cell apoptosis through down-regulation of NOB1 expression. PMID: 27505862
10. we suggest that targeting miR-192 and NOB1 is a novel strategy which will assist in the development of new therapeutics that will be used in the future to prevent and treat prostate cancer. PMID: 26743688
11. The results suggested that NOB1 is important in OSCC development and serves as a candidate indicator of aggressiveness and a therapeutic target of oral squamous cell carcinoma. PMID: 26370469
12. These results suggest that NOB1 may act as an important regulator in non-small cell lung cancer growth and could be a therapeutic target of nonsmall cell lung cancer. PMID: 26178254
13. Downregulation of miR-326 inhibited tumor proliferation and tumor metastasis by directly targeting NOB1 in colorectal carcinoma. Upregulation of miR-326 in CRC cells was revealed to be associated with a feedback loop involving downregulation of the NOB1. PMID: 25760058
14. Enhanced expression of NOB1 is related to poor overall survival and progression-free survival in patients with resected non-small cell lung cancer. PMID: 25450647
15. Enhanced expression of NOB1 gene plays an important role in the occurrence and development of NSCLC. PMID: 24272676
16. NOB1 is involved in the malignant transformation and tumorigenecity of human prostate cancer cells. PMID: 25169742
17. These findings suggest that NOB1 may be a potential prognostic indicator for PCa. PMID: 25503472
18. NOB1 gene silencing by lentivirus-mediated RNA interference can inhibit tumor growth by inducing apoptosis of cancerous human colorectal cells. PMID: 25624720
19. NOB1 protein in gastric cancer tissue and adjacent normal tissue was diffusely expressed in the cytoplasm and nucleus. NOB1 protein and mRNA expression was higher than normal in gastric cancer tissue and was directly related to tumor size. PMID: 26122232
20. Downregulation of NOB1 was able to significantly activate constitutive phosphorylation of p38 MAPK, which might contribute to the inhibition of papillary thyroid carcinoma cell growth. PMID: 25231838
21. NOB1 expression was associated with poor prognosis in ccRCC patients. PMID: 25420906
22. These findings provide evidence that Nob1 is an indicator of poor prognosis in prostate carcinoma. PMID: 24493285
23. NOB1 depletion may inhibit osteosarcoma development by increasing E-cadherin and beta-catenin expression. PMID: 24714960
24. NOB1 is an important regulator of the tumorigenic properties of human non-small cell lung cancer. PMID: 24452698
25. NOB1 expression status was closely correlated with important histopathologic characteristics and the recurrence and metastasis of prostate carcinomas. PMID: 24228091
26. aberrant expression of NOB1 in breast infiltrating ductal carcinoma is possibly involved with tumorigenesis and development, and the NOB1 protein could act as a potential biomarker for prognosis assessment of breast infiltrating ductal carcinoma. PMID: 24133592
27. The expression level of the NOB1 gene in the thyroid may play a key role in the occurrence and development of papillary thyroid carcinoma. PMID: 23685895
28. NOB1 promotes glioma cell growth and migration and could be a candidate for molecular targeting during gene therapy treatments of glioma. PMID: 23911301
29. NOB1 expression is higher in colorectal cancer than in normal colorectal tissues. Expression was not correlated to such tumor characteristics as gender, age, histological differentiation grade, depth of invasion and lymph node metastasis. PMID: 22445998
30. These results suggested that NOB1 may act as an oncogenic factor in ovarian cancer PMID: 21287298
31. Nob1 is an important regulator of the tumorigenic properties of human hepatocellular carcinoma and could be used as a candidate therapeutic target. PMID: 21573803
32. Cloning, expression and characterization of the human NOB1 gene and its products. PMID: 16172919

显示更多

收起更多

HGNC: 29540

OMIM: 613586

KEGG: hsa:28987

STRING: 9606.ENSP00000268802

UniGene: Hs.271695